Sökning: onr:"swepub:oai:DiVA.org:uu-307551" > Lenalidomide-bendam...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 04540naa a2200481 4500 | |
001 | oai:DiVA.org:uu-307551 | |
003 | SwePub | |
008 | 161117s2016 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3075512 URI |
024 | 7 | a https://doi.org/10.1182/blood-2016-03-7040232 DOI |
040 | a (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Albertsson-Lindblad, Alexandrau Skane Univ Hosp, Dept Oncol, SE-22185 Lund, Sweden.4 aut |
245 | 1 0 | a Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma |
264 | 1 | b American Society of Hematology,c 2016 |
338 | a print2 rdacarrier | |
520 | a For elderly patients with mantle cell lymphoma (MCL), there is no defined standard therapy. In this multicenter, open-label phase 1/2 trial, we evaluated the addition of lenalidomide (LEN) to rituximab-bendamustine (R-B) as first-line treatment for elderly patients with MCL. Patients >65 years with untreated MCL, stages II-IV were eligible for inclusion. Primary end points were maximally tolerable dose (MTD) of LEN and progression-free survival (PFS). Patients received 6 cycles every four weeks of L-B-R (L D1-14, B 90 mg/m(2) IV, days 1-2 and R 375 mg/m(2) IV, day 1) followed by single LEN (days 1-21, every four weeks, cycles 7-13). Fifty-one patients (median age 71 years) were enrolled from 2009 to 2013. In phase 1, the MTD of LEN was defined as 10 mg in cycles 2 through 6, and omitted in cycle 1. After 6 cycles, the complete remission rate (CRR) was 64%, and 36% were MRD negative. At a median follow-up time of 31 months, median PFS was 42 months and 3-year overall survival was 73%. Infection was the most common nonhematologic grade 3 to 5 event and occurred in 21 (42%) patients. Opportunistic infections occurred in 3 patients: 2 Pneumocystis carinii pneumonia and 1 cytomegalovirus retinitis. Second primary malignancies (SPM) were observed in 8 patients (16%). LEN could safely be combined with R-B when added from the second cycle in patients with MCL, and was associated with a high rate of CR and molecular remission. However, we observed a high degree of severe infections and an unexpected high number of SPMs, which may limit its use. This trial is registered at www.Clinicaltrials.gov as #NCT00963534. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Klinisk laboratoriemedicin0 (SwePub)302232 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Clinical Laboratory Medicine0 (SwePub)302232 hsv//eng |
653 | a Patologi | |
653 | a Pathology | |
700 | 1 | a Kolstad, Arneu Oslo Univ Hosp, Dept Oncol, Oslo, Norway.4 aut |
700 | 1 | a Laurell, Annau Univ Uppsala Hosp, Dept Oncol, Uppsala, Sweden.4 aut0 (Swepub:uu)annajohn |
700 | 1 | a Raty, Riikkau Helsinki Univ Hosp, Dept Hematol, Helsinki, Finland.4 aut |
700 | 1 | a Gronbaek, Kirstenu Rigshosp, Dept Hematol, Copenhagen, Denmark.4 aut |
700 | 1 | a Sundberg, Janu Skane Univ Hosp, Dept Oncol, SE-22185 Lund, Sweden.4 aut |
700 | 1 | a Pedersen, Lone Bredou Rigshosp, Dept Hematol, Copenhagen, Denmark.4 aut |
700 | 1 | a Ralfkiaer, Elisabethu Rigshosp, Dept Pathol, Copenhagen, Denmark.4 aut |
700 | 1 | a Karjalainen-Lindsberg, Marja-Liisau Univ Helsinki, Cent Hosp, Dept Pathol, Helsinki, Finland.4 aut |
700 | 1 | a Sundström, Christeru Uppsala universitet,Klinisk och experimentell patologi,Department of Pathology, Uppsala University Hospital, Uppsala, Sweden; and.,Rose-Marie Amini4 aut0 (Swepub:uu)chrisund |
700 | 1 | a Ehinger, Matsu Univ Lund Hosp, Dept Pathol Cytol, Lund, Sweden.4 aut |
700 | 1 | a Geisler, Christianu Rigshosp, Dept Hematol, Copenhagen, Denmark.4 aut |
700 | 1 | a Jerkeman, Matsu Skane Univ Hosp, Dept Oncol, SE-22185 Lund, Sweden.4 aut |
710 | 2 | a Skane Univ Hosp, Dept Oncol, SE-22185 Lund, Sweden.b Oslo Univ Hosp, Dept Oncol, Oslo, Norway.4 org |
773 | 0 | t Bloodd : American Society of Hematologyg 128:14, s. 1814-1820q 128:14<1814-1820x 0006-4971x 1528-0020 |
856 | 4 | u https://ashpublications.org/blood/article-pdf/128/14/1814/1396178/1814.pdf |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-307551 |
856 | 4 8 | u https://doi.org/10.1182/blood-2016-03-704023 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.